Ribo's RBD1016 Receives EMA Orphan Drug Designation
BEIJING and GOTHENBURG, Sweden — Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo) have exciting news to share. The European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to their innovative candidate, RBD1016, aimed at treating Hepatitis D Virus (HDV) infection. This designation is a significant milestone for Ribo as it underscores the importance of their work in addressing unmet medical needs.
Understanding Orphan Drug Designation
The EMA's ODD is specifically designated for investigational therapies targeting severe and chronically debilitating rare diseases, which affect fewer than five in 10,000 individuals in the European Union. Achieving this status means that Ribo can accelerate the progression of RBD1016 towards commercial availability and patient access, providing essential support for development.
RBD1016's Mechanism of Action
At the core of RBD1016 is Ribo's proprietary siRNA platform, GalNAc-platform RiboGalSTAR™, validated by multiple clinical studies. This candidate is particularly designed to selectively silence harmful viral factors associated with HDV infection. Currently, the efficacy of RBD1016 is under investigation in global Phase II clinical trials, with significant hope for favorable outcomes. Dr. Li-Ming Gan, Co-CEO and Global Head of R&D, commented on the importance of this milestone, stating, "This designation is a significant regulatory milestone that enhances the development and commercial potential of RBD1016. It validates our strategy of targeting severe diseases with high unmet need through innovative RNA interference technology."
The Urgent Need for Effective HDV Treatments
Hepatitis D Virus (HDV) represents a crucial challenge in the realm of viral hepatitis. It is the most critical form of this disease and can only occur alongside a hepatitis B virus (HBV) infection. HDV substantially accelerates diseases of the liver, heightening the risk of severe complications such as cirrhosis, liver failure, and hepatocellular carcinoma. Globally, it is estimated that between 12 to 20 million people are affected by HDV. Sadly, treatment options remain limited, leaving many patients without effective solutions.
Increased Awareness and Diagnosis
Despite the risks associated with HDV, many individuals remain undiagnosed. There is a pressing call for increased awareness and more diagnostic efforts to identify those affected. As healthcare professionals and researchers work toward better intervention strategies, the development of targeted therapies like RBD1016 can pave the way for more effective and sustained treatment options for patients.
About Ribo Life Science
Suzhou Ribo Life Science Co. Ltd. stands as a leader in the advancement of RNAi technology, especially in the industrialization of oligonucleotide drugs within China. The company has built a comprehensive oligonucleotide therapeutic platform that integrates a complete suite of technologies, leading to a robust drug development capability and a strong pipeline of siRNA products.
About Ribocure Pharmaceuticals AB
Ribocure Pharmaceuticals AB serves as the international research and development center for Ribo, located in Gothenburg, Sweden. This strategic location allows Ribo to engage with a broader scientific community while advancing its clinical programs.
Frequently Asked Questions
What is the purpose of RBD1016?
RBD1016 is a therapeutic candidate designed to treat Hepatitis D Virus infection by targeting and silencing key viral factors.
What does Orphan Drug Designation mean?
It indicates that the drug is intended for a rare disease, which allows for various incentives that can help expedite research, development, and market access.
Who is behind Ribo Life Science?
Ribo Life Science is a pioneering company focused on RNAi technology and oligonucleotide drug development, with a robust pipeline in this area.
What are the potential complications of HDV?
Hepatitis D Virus can lead to severe liver diseases, including cirrhosis and liver cancer, particularly in individuals co-infected with HBV.
How is RBD1016 being tested?
RBD1016 is currently undergoing global Phase II clinical trials to assess its efficacy and safety in treating HDV infection.
